Astria Therapeutics, Inc. (ATXS)
Automate Your Wheel Strategy on ATXS
With Tiblio's Option Bot, you can configure your own wheel strategy including ATXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATXS
- Rev/Share 0.0
- Book/Share 4.9873
- PB 1.0467
- Debt/Equity 0.0175
- CurrentRatio 17.386
- ROIC -0.4228
- MktCap 294586524.0
- FreeCF/Share -1.663
- PFCF -3.0539
- PE -2.8025
- Debt/Assets 0.0163
- DivYield 0
- ROE -0.3331
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ATXS | Cantor Fitzgerald | -- | Overweight | -- | $47 | April 29, 2025 |
| Initiation | ATXS | JMP Securities | -- | Mkt Outperform | -- | $26 | Jan. 31, 2025 |
News
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
Published: June 06, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined i.
Read More
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025. Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from.
Read More
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on May 30, 2025. Raffi Tachdjian, M.D., Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, L.
Read More
Astria Therapeutics: A High-Conviction Bet On HAE
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation.
Read More
About Astria Therapeutics, Inc. (ATXS)
- IPO Date 2015-06-25
- Website https://www.astriatx.com
- Industry Biotechnology
- CEO Ms. Jill C. Milne Ph.D.
- Employees 78